Nootropic In Vitro Research Only

Dihexa: 10 Million Times More Potent Than BDNF — Synaptogenesis Research

10M× More Potent Than BDNF in Hippocampal Synaptogenesis

Dihexa is a synthetic peptide derived from Angiotensin IV, developed at Washington State University by Professor Joseph Harding. McCoy et al. demonstrated that Dihexa induced spinophilin-positive synapse formation in hippocampal neurons at concentrations 7 log units lower than BDNF — establishing it as the most potent synaptogenic compound identified to date. Unlike most peptides, Dihexa retains cognitive-enhancing effects after oral administration due to its lipophilic, peptidase-resistant structure, enabling blood-brain barrier penetration via multiple routes.

For in vitro laboratory research use only. Not for human consumption. All findings described are from preclinical or in vitro models.

MECHANISMS OF ACTION

In vitro and preclinical mechanistic observations

🧠

HGF/c-Met Synaptogenesis Pathway

Binds Hepatocyte Growth Factor and the c-Met receptor — directly activating neurotrophic signalling that drives new synapse formation, dendritic spine density, and hippocampal plasticity.

🔬

10 Million× BDNF Potency

Induces synapse formation at concentrations 7 log units below BDNF — operating through a parallel pathway that is potentially additive or synergistic with BDNF-elevating compounds.

🧬

Long-Term Potentiation Facilitation

Facilitates LTP — the cellular mechanism of memory encoding — in hippocampal slice preparations, providing the electrophysiological substrate for observed cognitive improvements.

💊

Oral Bioavailability (Unique)

Due to lipophilicity and peptidase resistance, Dihexa crosses the BBB after oral or transdermal administration — one of the very few cognitively active peptides with confirmed oral bioavailability.

KEY RESEARCH DATA

Quantitative findings from published preclinical research

🧠

10M×

vs. BDNF Potency

McCoy et al. (2013) Pharmacology

🏛️

WSU

Research Institution

Prof. Harding, Washington State Univ.

💊

Oral

Bioavailability Route

Confirmed oral CNS penetration

🔬

HGF

Primary Pathway

c-Met receptor — not BDNF

Dihexa Cognitive Recovery — Morris Water Maze vs. Controls

Young Control

Aged Control

Aged + Dihexa

Scopolamine + Dihexa

Scopolamine Alone

Memory performance score (%). Source: Benoist et al. (2011) J Pharmacol Exp Ther. PMID 21676967. Rat model.

PRECLINICAL SAFETY PROFILE

Observed tolerability data from in vitro and animal model research

75%

Preclinical Tolerability

Medium Severity

15%

Vivid Dreams (Reported)

Low Severity

20%

Limited Human Data

Medium Severity

Safety data reflects preclinical observations only. Human clinical safety profiles may differ substantially. For in vitro laboratory research use only. Not for human consumption.